Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / MiNK Therapeutics / Neurocrine Biosciences

MiNK Therapeutics & Neurocrine Biosciences

2 shared events · Importance 3 · Last updated Apr 15, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
56.666666666666664
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
Shared Events (2)
100
Business
Neurocrine Acquires Soleno for $2.9B
MiNK Therapeutics: MiNK Therapeutics is being acquired by Neurocrine Biosciences for $2.9 billion, representing a significant premium for its shareholders. Its product, VYKAT XR, is a key asset in this transaction.
Neurocrine Biosciences: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio in endocrinology and rare diseases with the addition of VYKAT XR. This acquisition is expected to accelerate revenue growth and diversify its product offerings.
Apr 06, 2026 · 6 articles
0
Business
Neurocrine Acquires Soleno for $2.9B
Neurocrine Biosciences: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio into metabolic disorders with the addition of VYKAT XR. This deal is seen as a strategic entry into the metabolic disease market.
Apr 06, 2026 · 6 articles
NEWSDESK
Explore this relationship live

Track how MiNK Therapeutics and Neurocrine Biosciences interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.